ANIK Financial Facts
Comprehensive income (loss): 9.26MTotal revenue: 25.79M
See Full Income Statement
Long-term deferred revenue: 59K
Total Liabilities and Stockholders' Equity: 231.06M
See Full Balance Sheet
Anika Therapeutics Inc. (ANIK) Earnings
|
Expand Research on ANIK
| Next EPS Date | 11/5/26 *Est. | EPS Growth Rate | +423.1% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +673.4% | Revenue Growth Rate | +15.5% *Last Qtr. |
| Average % Move 1-Wk after EPS | +8.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
7/29/26  |
Q226 | $0.42 | $0.02 | +$0.40 | $32.6M | $29.21M | = |  | | Details | |
| 4/29/26 | Q126 | $0.27 | -$0.18 | +$0.45 | $29.6M | $28.11M | = | | | Details | |
| 2/26/26 | Q425 | $0.31 | -$0.14 | +$0.45 | $30.6M | $29.1M | = | | | Details | |
| 11/5/25 | Q325 | $0.04 | -$0.18 | +$0.22 | $27.8M | $27.8M | N/A | | | Details | |
| 7/30/25 | Q225 | -$0.13 | -$0.08 | -$0.05 | $28.22M | $28.15M | N/A | | | Details | |
| 5/9/25 | Q125 | -$0.06 | -$0.04 | -$0.02 | $26.17M | $28.13M | N/A | | | Details | |
| 3/12/25 | Q424 | -$0.03 | -$0.23 | +$0.20 | $30.6M | $29M | N/A | | | Details | |
| 2/27/25 |
Q424 | N/A | $0.23 | N/A | N/A | $45.72M | = | N/A | N/A |
